Human CIK Cells Loaded with Gold Nanoprisms as Theranostic Platform for Targeted Photoacoustic Imaging and Enhanced Immuno-Photothermal Combined Therapy

Jingjing Zhang,Gabriel Alfranca,Lijun Ma,Daxiang Cui,Weilin Jin,Yuming Yang,Yafei Hou,Jian Ni,Chunlei Zhang,Yanlei Liu,Jesus Martinez De La Fuente,Fangfang Xia,Caixia Yue,Yao Yang

doi:10.5101/nbe.v8i3.p112-127

Abstract

Human CIK Cells Loaded with Gold Nanoprisms as Theranostic Platform for Targeted Photoacoustic Imaging and Enhanced Immuno-Photothermal Combined Therapy

Highlights

Stomach cancer (GC) is the fourth most common cancer and the second leading cause of cancer-related death worldwide [1]-[3]
The results show that human cytokine induced killer (CIK) cells labeled with CD3 antibody-conjugated PEGylated gold nanoprisms could target gastric cancer in vivo, realize photoacoustic imaging and photothermal therapy of gastric cancer, and markedly enhance CIK immunotherapeutic efficacy
Our results provide a new strategy to treat gastric cancer, and offer proof-of-principle of practicality of CIK combined with photothermal therapy (PTT) based on human CIK cells labeled with CD3 antibody conjugated PEGylated gold nanoprisms, http://www.nanobe.org exhibiting potential clinical applications such as theranostics of gastric cancers in middle and late stages and post-operation tumor patients in near future

Summary

Introduction

Stomach cancer (GC) is the fourth most common cancer and the second leading cause of cancer-related death worldwide [1]-[3] It ranks No 2 among all malignant tumors in China according to the latest cancer disease spectrum [4]. Dendritic cells (DCs) and cytokine induced killer (CIK) cells have been broadly used for clinical therapy of post-operation tumor patients, and achieved better therapeutic efficacy [6]-[9]. CIK cells are a heterogeneous subset of exvivo expanded T lymphocytes [10]-[12]. They present a mixed T-NK phenotype and are endowed with the MHC-unrestricted antitumor activity, which means it can kill cancer cells without attacking the normal cells [13, 14]. It is very necessary to develop new therapeutic strategies that could enhance CIK therapeutic effects and/or improve synergistic combined therapy

Methods

Discussion

Conclusion